Madlen Gazarian

Summary

Affiliation: University of New South Wales
Country: Australia

Publications

  1. ncbi Long-term reduction in adverse drug events: an evidence-based improvement model
    Madlen Gazarian
    Paediatric Therapeutics Program, School of Women s and Children s Health, University of New South Wales, New South Wales, Australia
    Pediatrics 129:e1334-42. 2012
  2. ncbi Patient based methods for assessing adverse events in clinical trials in rheumatology. Progress report for the OMERACT Drug Toxicity Working Party. Outcome Measures in Rheumatology
    M Gazarian
    School of Paediatrics, University of New South Wales and Sydney Children s Hospital, Sydney, Australia
    J Rheumatol 26:207-9. 1999
  3. ncbi EBM in practice: paediatrics
    M Gazarian
    School of Women s and Children s Health, University of New South Wales, Sydney Children s Hospital
    Med J Aust 174:586-7. 2001
  4. ncbi Off-label use of medicines: consensus recommendations for evaluating appropriateness
    Madlen Gazarian
    University of New South Wales, Sydney, NSW, Australia
    Med J Aust 185:544-8. 2006
  5. ncbi Delivering better medicines to children: need for better integration between the science, the policy, and the practice
    Madlen Gazarian
    Paediatric Therapeutics Program, School of Women s and Children s Health, University of New South Wales and Sydney Children s Hospital, New South Wales, Australia
    Paediatr Drugs 11:41-4. 2009
  6. ncbi Training pediatric clinical pharmacology and therapeutics specialists of the future: the needs, the reality, and opportunities for international networking
    Madlen Gazarian
    Paediatric Therapeutics Program, School of Women s and Children s Health, University of New South Wales and Sydney Children s Hospital, New South Wales, Australia
    Paediatr Drugs 11:63-6. 2009
  7. ncbi Changes in anticonvulsant prescribing for Australian children: implications for Quality Use of Medicines
    Simon A Cohen
    Department of Paediatric Neurology, Sydney Children s Hospital, Randwick, Australia
    J Paediatr Child Health 48:490-5. 2012
  8. ncbi What's in a name? Brand name confusion and generic medicines
    Shane L Carney
    John Hunter Hospital, Newcastle, NSW
    Med J Aust 195:650-1. 2011
  9. ncbi The road to consensus: considerations for the safe use and prescribing of COX-2-specific inhibitors
    Madlen Gazarian
    Med J Aust 177:572-3; author reply 573. 2002

Collaborators

Detail Information

Publications9

  1. ncbi Long-term reduction in adverse drug events: an evidence-based improvement model
    Madlen Gazarian
    Paediatric Therapeutics Program, School of Women s and Children s Health, University of New South Wales, New South Wales, Australia
    Pediatrics 129:e1334-42. 2012
    ..To develop and test an evidence-based model for reducing medication errors and harm in hospitalized children...
  2. ncbi Patient based methods for assessing adverse events in clinical trials in rheumatology. Progress report for the OMERACT Drug Toxicity Working Party. Outcome Measures in Rheumatology
    M Gazarian
    School of Paediatrics, University of New South Wales and Sydney Children s Hospital, Sydney, Australia
    J Rheumatol 26:207-9. 1999
    ..Four instruments were ascertained and evaluated using the guidelines developed by the working party. This report outlines the progress and preliminary results of these activities...
  3. ncbi EBM in practice: paediatrics
    M Gazarian
    School of Women s and Children s Health, University of New South Wales, Sydney Children s Hospital
    Med J Aust 174:586-7. 2001
    ..The health outcomes of these efforts need to be systematically evaluated...
  4. ncbi Off-label use of medicines: consensus recommendations for evaluating appropriateness
    Madlen Gazarian
    University of New South Wales, Sydney, NSW, Australia
    Med J Aust 185:544-8. 2006
    ..This will reduce inappropriate use, enhance patient safety by reducing exposure to unnecessary risk, and may stimulate more clinically relevant medicines research...
  5. ncbi Delivering better medicines to children: need for better integration between the science, the policy, and the practice
    Madlen Gazarian
    Paediatric Therapeutics Program, School of Women s and Children s Health, University of New South Wales and Sydney Children s Hospital, New South Wales, Australia
    Paediatr Drugs 11:41-4. 2009
    ..Delivering on the promise of better medicines for children, wherever in the world they may be, depends on achieving successful integration between the science, the policy, and the practice of pediatric medicines...
  6. ncbi Training pediatric clinical pharmacology and therapeutics specialists of the future: the needs, the reality, and opportunities for international networking
    Madlen Gazarian
    Paediatric Therapeutics Program, School of Women s and Children s Health, University of New South Wales and Sydney Children s Hospital, New South Wales, Australia
    Paediatr Drugs 11:63-6. 2009
    ....
  7. ncbi Changes in anticonvulsant prescribing for Australian children: implications for Quality Use of Medicines
    Simon A Cohen
    Department of Paediatric Neurology, Sydney Children s Hospital, Randwick, Australia
    J Paediatr Child Health 48:490-5. 2012
    ..Our objective is to describe recent anticonvulsant prescribing patterns in the Australian paediatric population, evaluating overall trends and extent of off-label prescribing of newer agents...
  8. ncbi What's in a name? Brand name confusion and generic medicines
    Shane L Carney
    John Hunter Hospital, Newcastle, NSW
    Med J Aust 195:650-1. 2011
    ..We need an urgent review of medicines labelling in Australia and New Zealand...
  9. ncbi The road to consensus: considerations for the safe use and prescribing of COX-2-specific inhibitors
    Madlen Gazarian
    Med J Aust 177:572-3; author reply 573. 2002